Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...

There’s no question, however, that the decision to abandon the twice-daily version introduces a significant delay to Pfizer’s plans to enter the obesity market, which has been transformed in ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

In vaccines, Pfizer plans to start a Phase 3 study for PCV ... study is critical for Pfizer’s entry into the lucrative obesity market. It is still in progress, with data expected in Q1-CY25.

Pfizer (NYSE:PFE) is undervalued, trading well below its historical and sector averages despite strong non-COVID revenue growth and cost optimizations. Its expanding pipeline in oncology, obesity ...

Pfizer wants to stay "aggressive in trying to break into the lucrative obesity market", advancing danuglipron (their oral weight-loss drug), and also exploring other mechanisms of action to ...

In his first public comments, Pfizer’s new innovation chief — once a Wall Street analyst skeptical of the company — said he was confident in the company’s obesity plans and shed light on ...